Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Inv. presentation
Appointed CFO
Quarterly results
CC transcript
VALEANT PHARMACEUTICALS INTERNATIONAL (VRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/01/2010 8-K Quarterly results
09/23/2010 8-K Other Events
09/22/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "VALEANT ANNOUNCES PRICING OF SENIOR NOTES"
09/17/2010 8-K Other Events
09/09/2010 8-K Form 8-K - Current report
09/07/2010 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Email Communication sent to employees of Valeant and Biovail dated September 7, 2010, and furnished pursuant to Item 7.01, “Regulation FD Disclosure.”"
08/12/2010 8-K/A Form 8-K - Current report [amend]
06/23/2010 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, among Valeant Pharmaceuticals International, Biovail Corporation, Biovail Americas Corp. and Beach Merger Corp",
"Commitment Letter, among Valeant Pharmaceuticals International, Biovail Corporation, Goldman Sachs Lenders Partners LLC, Goldman Sachs Bank USA, Morgan Stanley Senior Funding, Inc. and Jefferies Finance LLC",
"Voting Agreement, among Valeant Pharmaceuticals International, Biovail Corporation and ValueAct, Inc",
"Employment Agreement, entered into as of June 20, 2010, by and between Biovail Corporation, Biovail Laboratories International SRL and J. Michael Pearson",
"Biovail Corporation Non-Executive Chairman and Biovail Laboratories International SRL President Agreement, by and between Biovail Corporation, Biovail Laboratories International SRL and William M. Wells"
06/21/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "VALEANT AND BIOVAIL AGREE TO MERGE Combination Creates Leader in Specialty Pharmaceuticals Accretive to Stockholders of Both Companies in First 12 Months Combined Operating Cash Flow on a Trailing 12-Month Basis of $575 Million $175 Million in Annual Cost Synergies Fully Captured by Second Year Strong Cash Flow to Support Future Growth and to Strengthen Balance Sheet"
06/02/2010 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financia...
Docs: "Membership Interest Purchase Agreement, by and among Valeant Pharmaceuticals International, Princeton Pharma Holdings LLC and the other parties named therein. †‡",
"Credit and Guaranty Agreement, by and among Valeant Pharmaceuticals International, the guarantors named therein, Goldman Sachs Bank USA and the other parties named therein. ‡",
"Pledge and Security Agreement, by and among Valeant Pharmaceuticals International, Goldman Sachs Bank USA and the other grantors named therein. ‡"
05/14/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/03/2010 8-K Quarterly results
Docs: "Purchase and Sale Agreement between the Registrant and ValueAct Capital Master Fund, L.P.",
"VALEANT PHARMACEUTICALS REPORTS 2010 FIRST QUARTER FINANCIAL RESULTS"
04/12/2010 8-K Form 8-K - Current report
04/07/2010 8-K Other Events, Financial Statements and Exhibits
Docs: "VALEANT PHARMACEUTICALS ANNOUNCES PRICING OF SENIOR NOTES"
04/06/2010 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "VALEANT PLANS SENIOR NOTES OFFERING"
04/05/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment to Employment Offer Letter, Bhaskar Chaudhuri and Valeant Pharmaceuticals International",
"Amendment to Employment Offer Letter, Rajiv De Silva and Valeant Pharmaceuticals International",
"Amendment to Employment Offer Letter, Elisa Karlson and Valeant Pharmaceuticals International",
"Amendment to Employment Offer Letter, Steve T. Min and Valeant Pharmaceuticals International"
03/29/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, between J. Michael Pearson and Valeant Pharmaceuticals International"
02/22/2010 8-K Form 8-K - Current report
01/11/2010 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/01/2009 8-K Form 8-K - Current report
11/10/2009 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amendments to By-laws of the registrant, effective as of November 4, 2009"
11/02/2009 8-K Quarterly results
Docs: "VALEANT PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS"
10/01/2009 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure
09/30/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "VALEANT TO ACQUIRE MAJOR AUSTRALIAN SKINCARE BRANDS"
08/14/2009 8-K Form 8-K - Current report
06/04/2009 8-K Form 8-K -- Current report
06/01/2009 8-K Form 8-K -- Current report
06/01/2009 8-K Form 8-K -- Current report
06/01/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "VALEANT PHARMACEUTICALS REPORTS ENCOURAGING FINAL RESULTS WITH TARIBAVIRIN PHASE IIB STUDY"
05/28/2009 8-K Form 8-K -- Current report
05/28/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "Consent of PricewaterhouseCoopers LLP, an Independent Registered Public Accounting Firm",
"Revised Part II, Item 6 - Selected Financial Data; Revised Part II, Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations; Revised Part II, Item 7A — Quantitative and Qualitative Disclosures about Market Risk; Revised Part II, Item 8 - Financial Statements and Supplementary Data; Revised Schedule II — Valuation and Qualifying Accounts and Reserves"
05/28/2009 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Unaudited pro forma condensed consolidated statement of operations"
05/28/2009 8-K Other Events, Financial Statements and Exhibits
Docs: "VALEANT ANNOUNCES INCREASE TO SECURITIES REPURCHASE PROGRAM"
05/22/2009 8-K/A Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Valeant Pharmaceuticals International, Descartes Acquisition Corp., Dow Pharmaceutical Sciences, Inc., and Harris Goodman, as Stockholder Representative †"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy